nterim guidance, first issued 25 January 2021, updated 15 June 2021, updated 19 November 2021, updated 23 February 2022, updated 18 August 2022
These WHO interim recommendations for use of the BBV152 COVAXIN vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
This document has been ...updated: version 15 March 2022.
The vaccine is formulated from an inactivated SARS-CoV-2 antigen and is presented in single dose vials and multidose vials of 5, 10 and 20 doses.
more
HIV treatment
Policy brief
July 2017
WHO/HIV/2017.18
Web annex 6: Injectable prostaglandins versus
placebo or no treatment
Evidence to Decision Framework
The World Health Organization (WHO) recommends the use of insecticide-treated nets (ITNs) and intermittent preventive treatment in pregnancy (IPTp) as a cost-effective intervention for the prevention of malaria during pregnancy in endemic areas. This study was conducted to investigate: (1) the exten...t of use of both IPTp and ITNs, and (2) conduct multinomial regression to identify factors affecting the optimal usage of IPTp and ITNs among women with a recent pregnancy in Senegal.
more
Web annex 5: Oxytocin and ergometrine versus placebo or no treatment
Evidence to decision framework
Lymphatic filariasis, commonly known as elephantiasis, is a neglected tropical disease. Infection
occurs when filarial parasites are transmitted to humans through mosquitoes. When a mosquito
with infective stage larvae bites a person, the parasites are deposited on the person’s skin from
where ...they enter the body. The larvae then migrate to the lymphatic vessels where they develop
into adult worms in the human lymphatic system.
more